A USA-based investment firm was founded with a focus on early stage healthcare companies. The firm currently has 34 companies in their portfolio with 4 exits. The firm invests in all 4 life science sectors and the typical check size ranges from $100K – 500K and typically helps fill out existing rounds once there is a lead investor in-place. The firm generally seeks to make investments into emerging life science companies in Pre-Seed, Seed and Series A stages. The firm is US focused in terms of geographic preference, but will occasionally look outside of the US.
The firm invests across all life science verticals and is open to all 4 sectors. The firm looks for novel technologies in biotech, medtech, digital health therapeutics, and diagnostics. In terms of biotech companies, the firm focuses on biotechnology platforms rather than single asset biotech companies. The firm is agnostic to both subsector and indication and is open to both pre-clinical therapeutic companies as well as all three stages of medical devices.
The firm is open to all types of management teams, with a goal to democratize who gets funding in the life science space. The firm is looking for diversity in the management team to combine ideas and skill set. The firm prefers to co-invest rather than lead.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Sharpen Your Sword at Digital RESI November and Slay the Dragons at RESI JPM San Francisco
By Dennis Ford, Founder and CEO of Life Science Nation, Creator of the RESI Conference Series
Successful fundraising campaigns begin in 2022. Planning your 2023 capital investor and licensing roadshow needs to start with a full-on run at Digital RESI November. Life Science Nation (LSN) is offering a bundle package for Digital RESI November and RESI JPM San Francisco to get your best foot forward for funding in 2023. Digital RESI November is a two-day dedicated virtual partnering event featuring 250 investors and strategic partners, most of whom also showing up for RESI San JPM Francisco for in-person meetings. This affords startups the opportunity to sort their partner target list and set up for a fruitful JPM week, kicking off your global 2023 partnering. The combination of virtual and in-person meetings is compelling (one thing we got out of Covid) as you can save time and money on travel, while still securing the key meetings with strategic players that are a fit for your exact stage of development and product set.
LSN knows hybrid events work, as we have procured some interesting metrics at our RESI Boston event in September. We saw 600 attendees show up to RESI Boston with an additional 300 for the virtual component. These numbers were evenly split by fundraising CEOs and scientist-entrepreneurs and capital investors and licensing partners. LSN also found that 250 of the sell-side attendees got a majority of the 2,000 meetings by making multiple requests and leveraging an appropriate follow-up process to the buy-side attendees. The numbers speak for themselves with an average of 8-12 meetings, with many having over 20 meetings. Securing a strategic partnership is a numbers game and sticking with a proven process to identify the right targets through our match-based partnering system and then going after meetings with these matched partners works.
LSN hosts five Redefining Early Stage Investments (RESI) events each year around the globe. Strategic partnering doesn’t work by attending one or two events. You need to generate some mojo and get yourself in front of the global players that are a fit. Virtually or in-person, it all starts with the initial dialogue that will develop into a relationship over multiple meetings, and eventually, a deal.
Check out the Digital RESI November and RESI San JPM Francisco bundle and and kick off your 2023 strategic partner roadshow in a few short weeks! RESI San JPM Francisco is one of the most compelling and dynamic meetings of the year with 1,200 attendees, and is usually sold out a week or so beforehand, so investing in the package now is a no-brainer!
RESI JPM San Francisco Pitch Application Open
By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN
The Redefining Early Stage Investments (RESI) San Francisco 2023 Innovator’s Pitch Challenge (IPC) application is now open!
RESI Boston saw nearly 60 early-stage companies across therapeutics, medical devices, diagnostics, digital health pitch in front of judging panels of investors and industry experts, accompanied by a full audience with standing room only. Each finalist company also prepares a posterboard to be showcased in the exhibit hall and competes for “RESI Cash” which attendees use to “invest” in their favorite presenters for the final prizes.
RESI JPM San Francisco is the biggest conference of the year, attracting nearly 1,200 attendees, and we are thrilled to return to an in-person format for the first time in three years. Participating in the IPC is a great way to boost your visibility and receive valuable feedback from investors and strategic partners. Do not miss out on the opportunity to pitch at one of the largest RESIs of the year, during the life science industry’s busiest week!
The deadline to apply is Wednesday, November 30, but we expect slots to fill very quickly and highly encourage early application submissions!
Hot Investor Mandate: VC Firm Invests Up to $30M in Medical Technology and Digital Health Sectors, Mainly Within Western Europe, But Open to Global Opportunities
A venture capital firm that was established in 2015 and is headquartered in Western Europe. The firm will consider pre-seed investments but is primarily looking to participate in the Seed to Series A financings of early-stage companies with typical pre-money valuation usually between USD 5 million and USD 30 million. Average ticket size is USD 0.5 million. The firm currently participates in equity investments as well as convertible debt. The firm historically has made around ten new investments per year. The firm is focused on partnering with companies based in Western Europe but will consider global opportunities.
The firm is primarily interested in investing in companies in the medical technology and digital health sectors but will also consider those in the wearables and diagnostics sector as well. The firm is open to all modalities within the medical technology and digital health sectors but prefers diagnostic companies to be focused on devices rather than genomics or in vitro diagnostics. The firm will not consider investments in biotech or pharma companies. The firm prefers to invest in pre-market technologies with some proof of pre-clinical data available and will only invest in Class I and Class II (510k) medical devices, avoiding Class III (PMA). The firm will consider companies across all disease indications but prefers to avoid complex disease indications such as the oncology space.
The firm is open to working with both inexperienced and experienced management teams. The firm looks to work with management teams that are efficient and work well together. The firm will sometimes take a board seat as determined on a case-by-case basis. The firm normally prefers to co-invest but will occasionally take a lead role in investments.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Hot Investor Mandate: Early-Stage Venture Fund Formed by Leading University Alumni Invests in All Life Science Sectors, Focusing on Seed to Series A Rounds
An early stage fund founded by a group of alumni from a leading university is based in the USA. The group currently has $100M, under management. The group focuses on Angel to Series B stage companies across various sectors, including pharmaceutical, medical device, services and tools, and digital health. The typical investment size is between $1M to $2M. The group also syndicates with other investors for larger investments. The firm looks to make investments across the globe.
The firm is currently looking for new opportunities in the life science space. The fund is opportunistic in terms of sectors, subsectors and indications. The fund typically invests in seed rounds and series A rounds. Historically, the fund has been active in life science companies developing innovative platform technologies and cross-disciplinary technologies.
The firm focuses on investments in private companies and typically invests in pre-clinical and early clinical stage companies with strong and experienced management teams. The firm will take a board seat or observer seat occasionally, depending on the investments.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Hot Investor Mandate: USA-Based Firm Explores Investment and Strategic Partnership Opportunities That Align With Their Existing Products, Including Surgical Robotics
A firm based in the USA works with early stage startups using a variety of structures, including co-development, equity investments, licensing, and M&A. The firm works with startups that have a strategic alignment with their firm and/or fit their parameters for a venture investment. The firm is a multi-stage investor and is interested in new technologies worldwide.
The firm is interested in new technologies that are strategically related to the company’s existing robotics surgery systems. The firm is interested in instruments and accessories that can be attached or used with its robotic for use in minimally invasive surgical and endobronchial procedures, and in technologies that improve the dexterity, precision and safety of surgical robotics. Technologies that support the vision/scope abilities of the firm’s systems are an area of interest, including 3DHD technologies, imaging agents and devices that can be used in conjunction with robotics, and non-imaging tools such as AI that enhances surgical vision. Additionally, the firm is interested in devices and digital health technologies used by surgeons and hospitals, such as technologies to improve workflow for surgical suites or which provide surgeons with additional data. The firm is interested in any indication area in which robotics is applicable; cancer diagnosis and treatment is a core area of interest. The firm is interested in working with companies at any stage of development.
The firm Surgical is flexible regarding different types of partnership, and is focused on achieving strategic alignment with their partners. The firm typically works alongside the partner to achieve integration between their existing technology and the new technology. While the firm will consider very early stage opportunities, typically a working prototype or demo is required for assessment.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Hot Investor Mandate: Leading Biopharmaceutical Seeks Licensing and Collaboration Opportunities For China and Global Market in Oncology, CNS, Autoimmune Disease, and More
One of the leading fully integrated biopharmaceutical companies in China has established three integrated R&D centers, with locations in USA and China. The firm has built a market-leading product portfolio in China. Its vigorous in-house R&D efforts and extensive R&D collaborations have made it a strategic cooperation partner with world leading innovative companies and research institutes. The firm is actively seeking for licensing/collaboration on development candidates with first-in-class or best-in-class potentials, and commercial products with substantial market opportunities in China and worldwide.
The firm is actively looking for innovative drug candidates in all stages in the therapeutic areas of Oncology, CNS, Autoimmune and Infectious disease, as well as a technology platform in Cell Therapy.
The firm is looking for companies with capacity and experience in implementing R&D plans. The firm is interested in assets from the US, Europe or other countries, and intends to introduce the product to the Chinese market.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
